---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-22-000033"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:41:12.862729+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook

## Summary
- Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).
- Net loss $14.6M ($0.40/share) vs $13.0M ($0.36/share) in Q2 2021.
- Gross margin improved to 75% from 74% due to production efficiencies.
- Added 18 new U.S. treatment centers (total 248); cash $166.8M.
- FY2022 revenue guidance reaffirmed $55M-$60M; operating expenses $100M-$105M.

## SEC filing metadata
- accession: 0001127537-22-000033
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/0001127537-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/lung-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-22-000033
- JSON: https://secwatch.observer/filing/0001127537-22-000033.json
- Plain text: https://secwatch.observer/filing/0001127537-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.